ID: ALA5266703

Max Phase: Preclinical

Molecular Formula: C19H17ClN2O

Molecular Weight: 324.81

Associated Items:

Representations

Canonical SMILES:  CCc1c(-c2ccccc2Cl)cnc(N)c1-c1ccc(O)cc1

Standard InChI:  InChI=1S/C19H17ClN2O/c1-2-14-16(15-5-3-4-6-17(15)20)11-22-19(21)18(14)12-7-9-13(23)10-8-12/h3-11,23H,2H2,1H3,(H2,21,22)

Standard InChI Key:  ALDNWIGPGPEFQA-UHFFFAOYSA-N

Associated Targets(Human)

Ubiquitin carboxyl-terminal hydrolase 7 837 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 324.81Molecular Weight (Monoisotopic): 324.1029AlogP: 4.92#Rotatable Bonds: 3
Polar Surface Area: 59.14Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.76CX Basic pKa: 6.78CX LogP: 5.07CX LogD: 4.98
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.72Np Likeness Score: -0.22

References

1. Li P, Liu HM..  (2020)  Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.,  191  [PMID:32092586] [10.1016/j.ejmech.2020.112107]

Source